20 results about "Prednisonum" patented technology

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

This invention provides a strain of *Lactobacillus plantarum*, and discloses the fermentation product of *Eucommia ulmoides* leaves, *Rehmannia glutinosa*, dried ginger, and *Dendrobium officinale* obtained by fermenting these herbs, along with its preparation method and applications. This fermentation product can directionally activate the phenylpropane biosynthetic pathway, inducing the generation of characteristic small molecule metabolites of polyphenols, particularly sanguranyl sulfadiazine (SSA). Moreover, compared to the raw materials, the fermentation product contains more active small molecule metabolites. Finally, experiments on zebrafish modeled with prednisone demonstrated that the fermentation product can significantly promote bone formation. The fermentation product mainly restores the expression levels of related genes to normal zebrafish gene expression levels by regulating these genes. Therefore, the fermentation product can be used to prepare foods or medicines that improve bone health.

The application provides a traditional Chinese medicine composition for treating chronic primary thrombocytopenia, a preparation and application thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 10-50 parts of Semen Euryae, 10-50 parts of Herba Epimedii, 10-50 parts of Radix Paeoniae Alba, 10-40 parts of Radix Rehmanniae, 10-40 parts of Folium Forsythiae and 3-20 parts of Cinnamomum Cassia. Pharmacological and pharmacodynamic experimental results prove that the traditional Chinese medicine composition can obviously reduce the bleeding grade of model mice, increase the platelets of model mice, has an effect equivalent to that of prednisone acetate, and is superior to that of Jinshuye mixture. The composition can effectively treat chronic primary thrombocytopenia by regulating the kidney and the spleen, and removing the root pathogenesis of deficiency of kidney yang caused by toxic evil lingering.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The invention provides a method for detecting the content of aflatoxin B1, B2, G1 and G2 in prednisolone through a fermentation process, which comprises the following steps: A) dissolving a sample to be detected by adopting a solvent, performing ultrasonic extraction, and filtering to obtain a liquid to be detected; b) preparing a mixed standard control solution of aflatoxin B1, B2, G1 and G2; and C) carrying out qualitative and quantitative analysis on the to-be-detected solution and the mixed standard control solution by adopting HPLC-MS / MS to obtain a detection result. According to the method disclosed by the invention, a rapid and simple pretreatment mode is combined with high performance liquid chromatography-triple quadrupole mass spectrometry, so that the aflatoxin B1, B2, G1 and G2 detection sensitivity is high, the separation degree and peak shape are good, and the detection result is reliable.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The invention provides an application of metformin in preparation of a medicine for preventing or treating immune checkpoint inhibitor related colitis. It is found through experiments that when the immune checkpoint inhibitor causes colitis, change of metabolic level represented by glycolysis caused by change of a PI3K / AKT / mTOR pathway in the colon is obviously accompanied, then Treg / Th17 steady state in the colon is affected, and a high inflammatory state is shown in the colon. According to the present invention, the influence on glycolysis and other metabolic pathways is achieved through the targeted interference of the metformin on the PI3K / AKT / mTOR pathway, the colitis caused by the immune checkpoint inhibitor can be significantly improved, the anti-tumor drug effect of the immune checkpoint inhibitor is not affected, and the method is generally superior to the original clinical methylprednisolone intervention scheme.

The invention relates to hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological hydrogel materials. The hydrogel comprises a prednisolone sodium phosphate hydrogel P-Gel skeleton and gold nanoparticles PCAu, wherein the gold nanoparticles PCAu are uniformly loaded on the P-Gel skeleton and are coated by procyanidine. According to the preparation method, a three-dimensional cross-linked network skeleton of PSP hydrogel P-Gel is self-assembled and constructed by utilizing ion coordination and hydrogen-bond interaction of prednisolone sodium phosphate PSP under the action of Ca < 2 + >, and the hydrogel PCAu-coated P-Gel is formed by uniformly loading gold nanoparticles PCAu which are green synthesized from procyanidine PC and have stable surfaces. The hydrogel can promote rapid repair of spinal cord injury and relieve far-end muscle atrophy and fibrosis; and meanwhile, the injectable self-healing hydrogel has the engineering advantages of injectability, self-healing and the like, and shows good clinical transformation potential.

Methods and compositions are provided for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib, a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

An object of the present invention is to provide a formulation technique for improving the solubility and safety of Prednisolone Valerate Acetate in an external pharmaceutical composition containing Prednisolone Valerate Acetate.SOLUTION: An external pharmaceutical composition comprising Prednisolone Valerate Acetate and propylene glycol monocaprylate.SELECTED DRAWING: None

The invention provides application of a KRAS inhibitor combined with glucocorticoid in preparation of a medicine for treating cancers, and belongs to the technical field of biological medicines. The invention provides a combined application of a KRAS inhibitor and glucocorticoid in preparation of a medicine for treating cancers. Compared with the single use of the KRAS inhibitor or prednisolone, the combined use of the KRAS inhibitor and prednisolone can more effectively inhibit the proliferation and survival of KRAS G12C mutated NSCLC cells and slow down the growth of tumor volume. In addition, prednisolone can relieve the acquired drug resistance problem of KRASi by blocking generation of TNF and I-type IFN induced by a KRAS inhibitor, and prednisolone and prednisolone have a synergistic anti-tumor effect. The two can be directly combined for medication, can also be prepared into a combined agent for treating cancers, and has a good clinical transformation prospect.

The invention provides an application of glutamine in treatment of primary nephrotic syndrome and an application thereof, and particularly relates to an application of a combination of glutamine or a derivative thereof or glutamine guat acid sodium and prednisone acetate in preparation of a medicine, and the medicine is used for preventing, relieving and / or treating the primary nephrotic syndrome. According to the application disclosed by the invention, the glutamine or the derivative thereof and the prednisone acetate are combined for use, so that the negative conversion time of the primary nephrotic syndrome can be effectively shortened, the times of later recurrence and infection are reduced, the prognosis effect is improved, and a new thought is provided for preventing, relieving and / or treating the primary nephrotic syndrome.

This invention discloses a quantitative analysis method for the blood concentrations of HYQ-169 and prednisolone and its application, belonging to the fields of medical testing and pharmaceutical analysis. The quantitative analysis method includes the following steps: preparing standard curve samples and quality control samples; adding internal standard solution; extracting with ethyl acetate; drying the supernatant and reconstituteing; separating using SPE; drying the fraction and reconstituteing again; detecting using UPLC-MS / MS; establishing a standard curve and obtaining a regression equation; adding internal standard solution to the plasma sample to be tested and processing it in the same way; calculating the blood concentrations of HYQ-169 and prednisolone according to the regression equation. This invention can simultaneously perform quantitative detection of two drug components with significantly different chemical properties in a single analysis, with high sensitivity, high accuracy, and fast analysis speed, providing a foundation for preclinical and clinical pharmacokinetic studies of HYQ-169.

Described herein are methods for reducing an antibody response to uricase therapy, improving the treatment of gout, reducing uric acid levels, and preventing and / or delaying infusion reactions. The methods may include administration of a uricase and a steroid as described herein.

The use of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone in the preparation of a drug for treating peripheral T-cell lymphoma (PTCL). The PTCL is preferably treatment-naïve PTCL. Other first-line and second-line drugs for treating PTCL may also be further used on the basis of the foregoing. A method for treating PTCL, the method comprising administering, to a patient, a therapeutically effective amount of a mitoxantrone hydrochloride liposome and cyclophosphamide, vincristine and prednisone. The combined administration of the drugs is safe and tolerable, has a small toxicity and few side effects, and can obtain a higher total objective remission rate (ORR) in treatment-naïve PTCL patients.

This invention discloses a method for simultaneously detecting cefepime and its metabolites, as well as prednisolone residues in milk. The method includes the following steps: taking a milk sample, extracting with acetonitrile, centrifuging, and collecting the supernatant; adding acetonitrile-saturated n-hexane for liquid-liquid extraction to remove fat; concentrating the extracted solution, reconstituted with phosphate buffer at pH 8.5 ± 0.2, purifying with a hydrophilic-lipophilic equilibrium solid-phase extraction column, eluting, concentrating, and reconstituted to obtain the test solution; and detecting the test solution using ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS / MS). This invention, through optimized pretreatment processes, particularly the dual purification strategy of "n-hexane degreasing + HLB solid-phase extraction" combined with precise pH adjustment, effectively removes complex fat and protein matrix interferences in milk, significantly reducing matrix effects; combined with optimized gradient elution procedures and multiple reaction monitoring (MRM) mass spectrometry conditions, it achieves simultaneous, rapid, and highly sensitive detection of cefepime, deacetylated cefepime, and prednisolone.

This invention provides a traditional Chinese medicine composition for treating and / or preventing intestinal adhesions after abdominal surgery, its preparation method, and its uses, belonging to the field of traditional Chinese medicine. The traditional Chinese medicine composition of this invention is prepared from the following raw materials in the indicated weight ratios: 8-12 parts of Sparganium rhizome, 8-12 parts of Curcuma rhizome, 8-12 parts of Peach kernel, 8-12 parts of Safflower, 24-36 parts of White Peony Root, 8-12 parts of Corydalis Rhizome, 8-12 parts of Sichuan Chinaberry Fruit, 8-12 parts of Frankincense, 8-12 parts of Myrrh, 12-18 parts of Poria cocos, 12-18 parts of Atractylodes macrocephala, and 4.8-7.2 parts of Licorice Root. This invention also provides a method for preparing this traditional Chinese medicine composition and its uses. The traditional Chinese medicine composition of this invention is used to treat and / or prevent intestinal adhesions after abdominal surgery, especially for intestinal adhesions caused by qi stagnation and blood stasis. It has significant efficacy and can achieve the same effect as chemical drugs such as prednisolone acetate and itopride. Moreover, toxicological tests have shown that the traditional Chinese medicine composition of this invention is safer to use and provides a new medication option for clinical use.